Request a Quote
News and Events
NJ Bio, Inc., hosted Dr. Yutaka Matsuda, the originator of novel AJICAP® linker technology from Ajinomoto Bio-Pharma Services
NJ Bio, Inc. was pleased to welcome Dr. Yutaka Matsuda and his colleague Mr. Hiroki Imai (Business Development Manager) from Ajinomoto Bio-Pharma Services to our headquarters in Princeton. Dr. Yutaka Matsuda is a double Ph.D. and an expert in site-specific chemical...
NJ Bio, Inc., hosted a discussion with the renowned researcher, Dr. Ravi Chari, on developing next generation ADCs
NJ Bio, Inc., had the great honor to welcome their esteemed SAB member, Fellow of The American Institute for Medical and Biological Engineering (AIMBE) and renowned biotechnology consultant, Dr. Ravi Chari, to their headquarters in Princeton, New Jersey in January...
NJ Bio, Inc., and Aarvik Therapeutics Inc. are excited to announce their collaboration to develop and commercialise next-generation ADCs for cancer therapy
NJ Bio, Inc. enters into a global license and assignment agreement with Aarvik Therapeutics Inc., to develop next-generation ADCs using their novel class of payloads and Aarvik’s innovative therapeutic antibodies. In the recently finalized agreement, Aarvik...
NJ Bio, Inc., hosted a discussion with the dynamic pharmaceutical executive and scientific leader, Dr. Thomas Nittoli
On 29th November 2022, NJ Bio, Inc., had the distinct pleasure of welcoming a good friend and mentor, Dr. Thomas (Tom) Nittoli from Regeneron Pharmaceuticals, Inc. to share his views on advancing conjugated antibodies and proteins from discovery to development of...
NJ Bio, Inc. hosted a discussion with the pioneers of next generation ADC Development, Dr. Junutula (Aarvik Therapeutics Inc.) and Dr. Mendelsohn (Exelixis Inc.)
On November 9th and 10th, 2022, NJ Bio, Inc. hosted two esteemed ADC researchers, Dr. Jagath Reddy Junutula, President, CEO, and Co-founder of Aarvik Therapeutics Inc. and Dr. Brian Mendelsohn, Executive Director, Antibody Drug Conjugates at Exelixis, Inc....
NJ Bio, Inc. proud partner, and expert speaker at the 5th Annual Targeted Protein Degradation Summit in Boston
NJ Bio, Inc. was proud to be a program partner at 5th Annual TPD Summit held in Boston between October 25 – 28, 2022. Our distinguished research leader, David C. Fry, Ph.D. was an expert speaker at the event. Dr. Fry has expertise in NMR analysis of proteins,...
NJ Bio, Inc. was awarded the 9th Annual World ADC Award For the Best Contract Research Provider Category
NJ Bio, Inc. was awarded the 9th Annual World ADC Award for Best Contract Research Provider category at the 13th Annual World ADC Conference 2022 held in San Diego. Through the years, the Annual World ADC Awards recognizes innovation, and leadership within the...
NJ Bio, Inc. Participates in Building the Bridge Between Industry and Academia Through Open Innovation at the Industry-Academia NOST Conclave held at IIT, Mumbai (Bombay), India
Over the years, NJ Bio, Inc. has stayed committed to the Antibody Drug Conjugates (ADCs) field by sponsoring several distinguished events in this space and has dedicated itself to educating the global community about this emerging area of innovation. We received yet...
NJ Bio is Thrilled to be a Senior Partner and Sponsor at the 13th Annual World ADC Conference in San Diego, CA.
NJ Bio is thrilled to be a Senior Partner and Sponsor at the 13th World ADC Conference to be held in San Diego, California on September 6-9, 2022. The World ADC Conference is the most comprehensive and longest standing Antibody-Drug Conjugate Conference that provides...
NJ Biopharmaceuticals LLC and JEOL Ltd. Are Excited to Announce Their Collaboration to Bring Innovative Drug Discovery Platform Solutions Using JEOL’s 800 MHz NMR!
PRINCETON, N.J.--(BUSINESS WIRE)--NJ Bio is procuring an 800 MHz NMR spectrometer with a cryogenic probe from JEOL. As part of this collaboration, NJ Bio will contribute its expertise in antibody drug conjugates, oligonucleotide conjugates, and other chemistries to...